Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Seven out of eight patients treated on Part A of the study are without disease progression at one-year median follow-up ATLAS™-identified neoantigens generate broad, sustained T cell responses...
-
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, hosted a KOL symposium...
-
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL...
-
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL...
-
Clinical stage programs GEN-009 and GEN-011 continue to advanceAnticipate GEN-011 IND filing in Q2Expect GEN-009 Phase 1/2a Part B readout in Q3GEN-011 Virtual Symposium planned for May 12th ...
-
CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first...
-
CAMBRIDGE, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
-
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
-
CAMBRIDGE, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
-
ATLASTM identifies Inhibigenstm that can undermine immunotherapyDosed first patient in Part B of GEN-009 neoantigen vaccine Phase 1/2a trialProgressed GEN-011 neoantigen cell therapy - IND filing...